EF Hutton Assumes Pasithea Therapeutics at Buy, Announces Price Target of $2
Portfolio Pulse from richadhand@benzinga.com
EF Hutton analyst Elemer Piros assumes Pasithea Therapeutics (NASDAQ:KTTA) with a Buy rating and announces a price target of $2.
June 01, 2023 | 8:50 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pasithea Therapeutics receives a Buy rating from EF Hutton analyst Elemer Piros with a price target of $2.
The Buy rating and price target announcement by EF Hutton analyst Elemer Piros is likely to have a positive short-term impact on Pasithea Therapeutics' stock price. Investors may see this as a signal of the company's potential growth and value, leading to increased demand for the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100